Cedars Sinai Medical Center Samuel Oschin Comp. Cancer Institute ( Site 0003) is a clinical research site located in Los Angeles, California, United States 90048.
Crixeo Health Trust Score: 58/100 (POOR). This profile has not yet been claimed by the site owner.
Cedars Sinai Medical Center Samuel Oschin Comp. Cancer Institute ( Site 0003) has participated in 1 clinical trials with 1 currently active.
Therapeutic areas: Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma (ccRCC), Kidney Cancer.
Sponsors: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
Trust Score: 58/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.
Cedars Sinai Medical Center Samuel Oschin Comp. Cancer Institute ( Site 0003) has a Crixeo Trust Score of 58/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.
Cedars Sinai Medical Center Samuel Oschin Comp. Cancer Institute ( Site 0003) has 1 clinical trials on record, with 1 currently active. Their work covers Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma (ccRCC), Kidney Cancer.
Cedars Sinai Medical Center Samuel Oschin Comp. Cancer Institute ( Site 0003) has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.
Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.